tradingkey.logo

Lifecore Biomedical Inc

LFCR
8.170USD
+0.130+1.62%
收盘 12/22, 16:00美东报价延迟15分钟
306.10M总市值
亏损市盈率 TTM

Lifecore Biomedical Inc

8.170
+0.130+1.62%

关于 Lifecore Biomedical Inc 公司

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Lifecore Biomedical Inc简介

公司代码LFCR
公司名称Lifecore Biomedical Inc
上市日期Feb 15, 1996
CEOJosephs (Paul)
员工数量406
证券类型Ordinary Share
年结日Feb 15
公司地址3515 Lyman Boulevard
城市CHASKA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编55318
电话19523684300
网址https://www.lifecore.com/
公司代码LFCR
上市日期Feb 15, 1996
CEOJosephs (Paul)

Lifecore Biomedical Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Paul Josephs
Mr. Paul Josephs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
233.33K
+75.00%
Mr. Ryan David Lake
Mr. Ryan David Lake
Chief Financial Officer
Chief Financial Officer
126.69K
+30.44%
Mr. Joshua E. Schechter
Mr. Joshua E. Schechter
Independent Director
Independent Director
89.67K
+13.25%
Mr. Thomas D. (Tom) Salus
Mr. Thomas D. (Tom) Salus
Chief Legal and Administrative Officer , Secretary
Chief Legal and Administrative Officer , Secretary
25.98K
-89.22%
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
24.55K
-44.27%
Mr. Nelson Obus
Mr. Nelson Obus
Independent Director
Independent Director
--
-100.00%
Mr. Humberto C. Antunes, M.D.
Mr. Humberto C. Antunes, M.D.
Independent Director
Independent Director
--
--
Ms. Stephanie Diaz
Ms. Stephanie Diaz
Investor Relations
Investor Relations
--
--
Mr. Paul H. Johnson
Mr. Paul H. Johnson
Independent Director
Independent Director
--
--
Mr. Matthew Edward Korenberg
Mr. Matthew Edward Korenberg
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Paul Josephs
Mr. Paul Josephs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
233.33K
+75.00%
Mr. Ryan David Lake
Mr. Ryan David Lake
Chief Financial Officer
Chief Financial Officer
126.69K
+30.44%
Mr. Joshua E. Schechter
Mr. Joshua E. Schechter
Independent Director
Independent Director
89.67K
+13.25%
Mr. Thomas D. (Tom) Salus
Mr. Thomas D. (Tom) Salus
Chief Legal and Administrative Officer , Secretary
Chief Legal and Administrative Officer , Secretary
25.98K
-89.22%
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
24.55K
-44.27%
Mr. Nelson Obus
Mr. Nelson Obus
Independent Director
Independent Director
--
-100.00%

收入明细

单位: USD更新时间: 3月4日 周二
单位: USD更新时间: 3月4日 周二
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Contract development and manufacturing organization ("CDMO")
17.81M
64.53%
Fermentation
8.52M
30.87%
Olive oil and wine vinegars
1.27M
4.60%
Technology
0.00
0.00%
地区USD
名称
营收
占比
United States
16.40M
59.42%
Switzerland
6.80M
24.64%
Ireland
1.10M
3.99%
Australia
1.10M
3.99%
Canada
700.00K
2.54%
其他
1.50M
5.43%
业务
地区
业务USD
名称
营收
占比
Contract development and manufacturing organization ("CDMO")
17.81M
64.53%
Fermentation
8.52M
30.87%
Olive oil and wine vinegars
1.27M
4.60%
Technology
0.00
0.00%

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Wynnefield Capital, Inc.
12.55%
Legion Partners Asset Management, LLC
11.91%
Greenhaven Road Investment Management, L.P.
9.86%
325 Capital LLC
5.77%
Laughing Water Capital, LP
5.07%
其他
54.83%
持股股东
持股股东
占比
Wynnefield Capital, Inc.
12.55%
Legion Partners Asset Management, LLC
11.91%
Greenhaven Road Investment Management, L.P.
9.86%
325 Capital LLC
5.77%
Laughing Water Capital, LP
5.07%
其他
54.83%
股东类型
持股股东
占比
Hedge Fund
30.51%
Investment Advisor
23.96%
Investment Advisor/Hedge Fund
18.29%
Research Firm
1.93%
Individual Investor
1.85%
Private Equity
0.17%
Bank and Trust
0.11%
Pension Fund
0.05%
Insurance Company
0.03%
其他
23.09%

机构持股

更新时间: 10月5日 周日
更新时间: 10月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q3
203
28.27M
75.45%
-763.44K
2025Q2
212
27.35M
73.90%
-2.82M
2025Q1
229
29.94M
81.56%
-2.38M
2024Q4
243
30.30M
82.90%
-2.02M
2024Q3
234
26.35M
84.61%
-494.37K
2024Q2
224
23.91M
77.61%
-4.44M
2024Q1
225
24.56M
80.40%
-3.68M
2023Q4
221
23.64M
77.94%
-3.68M
2023Q3
229
20.71M
68.28%
-6.48M
2023Q2
237
20.72M
68.32%
-8.44M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Wynnefield Capital, Inc.
4.70M
9.16%
--
--
Jun 30, 2025
Legion Partners Asset Management, LLC
4.43M
8.63%
--
--
Jun 30, 2025
Greenhaven Road Investment Management, L.P.
3.69M
7.19%
+78.69K
+2.18%
Jun 30, 2025
325 Capital LLC
2.16M
4.21%
+1.00
+0.00%
Sep 02, 2025
Laughing Water Capital, LP
1.90M
3.7%
--
--
Sep 02, 2025
David Capital Partners, LLC
1.80M
3.51%
+148.00K
+8.94%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
1.72M
3.35%
+90.16K
+5.52%
Jun 30, 2025
The Vanguard Group, Inc.
1.61M
3.13%
+63.30K
+4.09%
Jun 30, 2025
Geode Capital Management, L.L.C.
775.49K
1.51%
+25.00K
+3.33%
Jun 30, 2025
GrizzlyRock Capital, LLC
734.53K
1.43%
+734.53K
--
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.04%
WisdomTree US SmallCap Fund
0.03%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Motley Fool Next Index ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
iShares Micro-Cap ETF
占比0.04%
WisdomTree US SmallCap Fund
占比0.03%
Global X Russell 2000 ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
Motley Fool Next Index ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Lifecore Biomedical Inc的前五大股东是谁?

Lifecore Biomedical Inc 的前五大股东如下:
Wynnefield Capital, Inc.持有股份:4.70M,占总股份比例:9.16%。
Legion Partners Asset Management, LLC持有股份:4.43M,占总股份比例:8.63%。
Greenhaven Road Investment Management, L.P.持有股份:3.69M,占总股份比例:7.19%。
325 Capital LLC持有股份:2.16M,占总股份比例:4.21%。
Laughing Water Capital, LP持有股份:1.90M,占总股份比例:3.70%。

Lifecore Biomedical Inc的前三大股东类型是什么?

Lifecore Biomedical Inc 的前三大股东类型分别是:
Wynnefield Capital, Inc.
Legion Partners Asset Management, LLC
Greenhaven Road Investment Management, L.P.

有多少机构持有Lifecore Biomedical Inc(LFCR)的股份?

截至2025Q3,共有203家机构持有Lifecore Biomedical Inc的股份,合计持有的股份价值约为28.27M,占公司总股份的75.45%。与2025Q2相比,机构持股有所增加,增幅为1.56%。

哪个业务部门对Lifecore Biomedical Inc的收入贡献最大?

在FY2023Q3,Contract development and manufacturing organization ("CDMO")业务部门对Lifecore Biomedical Inc的收入贡献最大,创收17.81M,占总收入的64.53%。
KeyAI